Merck, Inc.

🇵🇭Philippines
Ownership
Subsidiary
Employees
-
Market Cap
$295.3B
Website
http://www.merck.ph
Clinical Trials
Related News

Study to Treat Uveitis Associated Macular Edema

Phase 2
Terminated
Conditions
Cystoid Macular Edema
Uveitis
First Posted Date
2005-06-14
Last Posted Date
2016-11-29
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
15
Registration Number
NCT00114062

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

Phase 1
Completed
Conditions
Cancer
Interventions
Drug: Ridaforolimus
First Posted Date
2005-06-03
Last Posted Date
2015-02-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
147
Registration Number
NCT00112372

A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)

First Posted Date
2005-06-03
Last Posted Date
2018-01-24
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
399
Registration Number
NCT00112437

An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

Phase 2
Completed
Conditions
Dyslipidemia
First Posted Date
2005-05-27
Last Posted Date
2017-02-17
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
575
Registration Number
NCT00111891

Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
Drug: vorinostat
Drug: bortezomib
First Posted Date
2005-05-26
Last Posted Date
2015-05-21
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
34
Registration Number
NCT00111813

MK0457 in Patients With Leukemia (0457-003)

First Posted Date
2005-05-25
Last Posted Date
2015-08-25
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
28
Registration Number
NCT00111683

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Drug: ridaforolimus
First Posted Date
2005-05-05
Last Posted Date
2015-11-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
39
Registration Number
NCT00110188
Locations
🇺🇸

Louis Warchaw Prostate Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

University of Wisconsin, Madison, WI, Madison, Wisconsin, United States

🇺🇸

Beth Israel Deaconess Medical Center/MGH/DFCI, Boston, Massachusetts, United States

and more 1 locations

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

First Posted Date
2005-04-29
Last Posted Date
2015-05-01
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
47
Registration Number
NCT00109538

V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

Phase 3
Completed
Conditions
Measles
Mumps
Varicella
Rubella
First Posted Date
2005-04-27
Last Posted Date
2017-04-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1027
Registration Number
NCT00109343

A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)

Phase 2
Completed
Conditions
Measles
First Posted Date
2005-04-26
Last Posted Date
2017-03-15
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1100
Registration Number
NCT00109278
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy